Search for Clinical Trial Results

Leukemia, Myelomonocytic, Acute - 25 Studies Found
Status | Study |
Completed |
Study Name: Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML Condition: Leukemia, Myelomonocytic, Acute Date: 2006-08-10 Interventions: Drug: XIAP antisense 2 days loading dose followed by weekly 2hr infusion |
Completed |
Study Name: Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia Condition: Leukemia, Myelomonocytic, Acute Date: 2010-07-30 Interventions: Drug: Erlotinib Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle wil |
Withdrawn |
Study Name: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Condition:
|
Completed |
Study Name: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Condition:
Interventions: Other: laboratory biomarker analysis Correlative studies |
Recruiting |
Study Name: A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Condition: Leukemia, Myelomonocytic, Chronic Date: 2017-01-24 Interventions:
|
Recruiting |
Study Name: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia Condition: Leukemia, Myelomonocytic, Chronic Date: 2016-06-15 Interventions: Drug: Tipifarnib Oral tablet Other Names: |
Recruiting |
Study Name: Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Condition: Chronic Myelomonocytic Leukemia (CMML) Date: 2015-08-27 Interventions: Drug: lenzilumab Other Names:
|
Active, not recruiting |
Study Name: A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Condition: Myelomonocytic Leukemia Date: 2013-01-24 Interventions: Drug: Ruxolitinib In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to |
Active, not recruiting |
Study Name: Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Condition: Chronic Myelomonocytic Leukemia Date: 2011-05-09 Interventions: Drug: Revlimid Dose escalation 5mg - 10mg - 15mg - 20mg in |
Completed |
Study Name: A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Condition: Chronic Myelomonocytic Leukemia Date: 2011-04-29 Interventions: Drug: 5-Azacitidine Administered on Days 1-7 of each Cycle |